ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

17.5 (USD) • At close March 14, 2025
Bedrijfsnaam ACADIA Pharmaceuticals Inc.
Symbool ACAD
Munteenheid USD
Prijs 17.5
Beurswaarde 2,918,807,500
Dividendpercentage 0%
52-weken bereik 14.15 - 20.68
Industrie Biotechnology
Sector Healthcare
CEO Mr. Stephen R. Davis J.D.
Website https://www.acadia-pharm.com

An error occurred while fetching data.

Over ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3

Vergelijkbare Aandelen

Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc.

HRMY

32.72 USD

Privia Health Group, Inc. logo

Privia Health Group, Inc.

PRVA

23.75 USD

AdaptHealth Corp. logo

AdaptHealth Corp.

AHCO

9.6 USD

Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

ROIV

10.66 USD

Axonics, Inc. logo

Axonics, Inc.

AXNX

70.98 USD

Denali Therapeutics Inc. logo

Denali Therapeutics Inc.

DNLI

15.15 USD

Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc.

PCRX

22.87 USD

OPKO Health, Inc. logo

OPKO Health, Inc.

OPK

1.74 USD

Insmed Incorporated logo

Insmed Incorporated

INSM

76.55 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)